pharmaphorum Daily Newsletter - 13th Jan.
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
JP Morgan Week kicks off in San Francisco – stay tuned between now through Wednesday for live updates from our editor-in-chief, Jonah Comstock. Day One available here.
In other news this Monday, Regeneron and Illumina have joined a $320 million investment in health data specialist Truveta that will support the creation of a major new genome project.
Elsewhere, Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn, while GSK confirmed that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1 billion upfront.
Meanwhile, Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, and Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.
In our longer reads today, learn more about the intricacies of effectively transitioning active clinical trials to the EU Clinical Trial Regulation, discover how data science and AI will transform life sciences in 2025, and delve into how manufacturers can streamline and speed the batch release process by embracing just three digital fundamentals.
All this and more on pharmaphorum.com.
News
Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.
强生公司 has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
荷商葛蘭素史克藥廠 confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.
Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.
Views & Analysis
Join us for live coverage of JP Morgan Healthcare Conference, where life sciences leaders congregate in San Francisco to network and make deals.
European Union lawmakers designed EU Clinical Trial Regulation 536/2014 to heighten interest within the healthcare industry for planning and conducting clinical trials in the EU.
On day 1 of JPM Week, join pharmaphorum as we hear about pharma's dealmaking plans and the changing pharma landscape.
Even for an industry that depends on relentless innovation to thrive, life sciences have seen remarkable advancements in recent decades.
领英推荐
As of late November 2024, the US Food & Drug Administration had recorded 46 voluntary drug recalls in the United States during the year, down slightly from previous years.
Podcasts & Videos
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options.
In a pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Sharmeen Roy, chief scientist at DoseMe, for a conversation on precision medicine tools and how pharmacokinetic (or PK) and pharmacodynamic (or PD) characteristics are a – long overdue – trend in pharma at the moment, from lead identification right up to final-stage clinical trials.
In this pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics, a company working in the in vivo cell therapy space.
Clinical research is full of challenges, from recruitment to data management to global resourcing. Working with a functional service provider (FSP) can be a great option for meeting these needs. But what exactly is an FSP, and what are the advantages to working with one? In this interview, brought to you by Advanced Clinical, Programme Directors Lori Fletcher and Amber Beimer speak with pharmaphorum editor-in-chief Jonah Comstock and clear up some misconceptions that FSPs are merely staffing agencies.
White Papers & Webinars
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’. This forward-looking session will explore how imagination and innovation are reshaping the future of healthcare.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the endeavours and developments that occurred since inaugural discussions 2023.
A panel of experts, including from IPG Health, have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.
An exclusive webinar, sponsored by Trueblue, explores how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge. Available now on demand.
In this webinar, sponsored by PurpleLab, learn how to gain a competitive edge by understanding physician prescribing behaviour in target markets. Available now on demand.
Homecare pharmacist ?? men's & mental health advocate ?? mindbodyspirit practitioner ??
1 个月Useful JPM week insights ?? ?? ?? ?? ?? ??